Login / Signup
VERVE-101: a promising CRISPR-based gene editing therapy that reduces LDL-C and PCSK9 levels in HeFH patients.
Takahiro Horie
Koh Ono
Published in:
European heart journal. Cardiovascular pharmacotherapy (2023)
Keyphrases
</>
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
genome wide
stem cells
mesenchymal stem cells
genome editing
bone marrow
low density lipoprotein
smoking cessation
replacement therapy